Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy

Author： Kim Ji-Won   Kim Jee   Im Seock-Ah   Lee Kyung-Hun   Kim Jin-Soo   Kim Tae-Yong   Han Sae-Won   Jeon Yoon   Oh Do-Youn   Kim Tae-You   Park In  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.72, Iss.5, 2013-11, pp. : 1023-1029

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

By Hayashi Naoki  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 523-531

Springer Publishing Company

Access to resources Recommend Favorite

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

By Lobbezoo Dorien   Kampen Roel   Voogd Adri   Dercksen M.   den Berkmortel Franchette   Smilde Tineke   Wouw Agnes   Peters Frank   Riel Johanna   Peters Natascha   Boer Maaike   Borm George   Tjan-Heijnen Vivianne  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 507-514

Springer Publishing Company

Access to resources Recommend Favorite

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients

By  

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 987-993

Spandidos Publications

Access to resources Recommend Favorite

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1351-1358

Spandidos Publications

Access to resources Recommend Favorite